Novozymes AS DRC (NVZMY)

Currency in USD
69.39
-0.46(-0.66%)
Closed·

NVZMY Financial Summary

Key Ratios

P/E Ratio37.59
Price/Book2.52
Debt / Equity15.13%
Return on Equity6.97%
Dividend Yield1.05%
EBITDA1.08B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of DKK (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1.58%
Dividend Yield
1.05%
Industry Median 2.37%
Annualised payout
0.73
Paid unevenly
5-Years Growth
+3.35%
Growth Streak

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 82.50
(+18.89% Upside)

Earnings

Latest Release
May 08, 2025
EPS / Forecast
0.4737 / 0.41
Revenue / Forecast
1.22B / 1.13B
EPS Revisions
Last 90 days

FAQ

What were Novozymes AS DRC's earnings for the latest quarter?

The Novozymes AS DRC EPS (TTM) is 1.58. Novozymes AS DRC reported sales of 1,077.60, net income of 186.00, and EPS of 0.47 for the latest quarter.

What was Novozymes AS DRC's net income for the latest quarter?

Novozymes AS DRC's net income for the latest quarter was 186.00.

How did Novozymes AS DRC's performance compare year-over-year in the latest quarter?

The company's revenue moved from 1,000.90 in the previous quarter to 1,077.60 in the latest quarter, and net income moved from 120.95 to 186.00 compared to the previous quarter.

What is Novozymes AS DRC's net profit margin on a TTM basis?

Novozymes AS DRC's trailing twelve months (TTM) net profit margin is 7.98%.

How does Novozymes AS DRC's debt to equity ratio compare to industry standards?

Novozymes AS DRC's total debt-to-equity ratio is 15.13%.

What is Novozymes AS DRC's return on investment on a TTM basis?

Novozymes AS DRC's trailing twelve months (TTM) return on investment (ROI) is 6.97%.

Did Novozymes AS DRC gain or lose cash last quarter?

In the latest quarter, Novozymes AS DRC's net change in cash was -30.50 million.

What were Novozymes AS DRC's total assets and liabilities in the latest quarter?

As of the latest quarter, Novozymes AS DRC reported total assets of 112,334.23 million and total liabilities of 8,730.16 million.

How has Novozymes AS DRC's total revenue grown this year?

Novozymes AS DRC's total revenue was 1,000.90 in the previous quarter and 1,077.60 in the latest quarter.

What is Novozymes AS DRC's gross margin on a TTM basis?

Novozymes AS DRC's trailing twelve months (TTM) gross margin is 52.73%.

What was Novozymes AS DRC's revenue per share for the latest quarter?

Novozymes AS DRC's revenue per share for the latest quarter was 177.59.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.